

Filter: Slovakia, minimal size of the groups n = 5

EQA round: VVV2/21 - Maternal Diagnostic Screening (Triple Test)

Deadline: 05.11.2021

| | | |
|--|--|--|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of the participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U _{AV} = expanded uncertainty of the assigned value (k = 2) | |

| Test | [unit] | Comparability | | | | | Comparability | | | | | | | |
|---|----------|---------------|-------|--------|------------------|------------------|---------------|-----------------|------------------|-----|-------|------------------|------------------|------------------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} |
| Set 1 | | | | | | | | | | | | | | |
| (238) free beta-hCG | [U/L] | | | | 10 | | | | | | | 10 | 9 | 90% |
| Samples and groups | | | | | | | | | | | | | | |
| Sample A1 | | 57,2 | 4,6 | 8,1 | 10 | | | | | | | 10 | 9 | 90% |
| (60) Roche | | 56,8 | 3,9 | 6,8 | 9 | 0 | CVPG | 55,8 | 0,97 | 15% | 47,4 | 64,2 | 9 | |
| Other | | | | | 1 | 0 | | | | | | | 1 | |
| ----- 1x 24 ----- | | | | | | | | | | | | | | |
| Sample B1 | | 56,5 | 3,6 | 6,3 | 10 | | | | | | | 10 | 9 | 90% |
| (60) Roche | | 55,6 | 2,4 | 4,3 | 9 | 0 | CVPG | 56,3 | 1,0 | 15% | 47,8 | 64,8 | 9 | |
| Other | | | | | 1 | 0 | | | | | | | 1 | |
| ----- 1x 24 ----- | | | | | | | | | | | | | | |
| (239) PAPP-A | [U/L] | | | | 13 | | | | | | | 10 | 10 | 100% |
| Samples and groups | | | | | | | | | | | | | | |
| Sample A1 | | 0,383 | 0,033 | 8,7 | 13 | | | | | | | 10 | 10 | 100% |
| (60) Roche | | 0,377 | 0,047 | 13 | 8 | 0 | CVPG | 0,377 | 0,011 | 15% | 0,32 | 0,434 | 8 | |
| Other | | | | | 5 | 0 | | | | | | | 2 | |
| ----- 2x 24, 3x 29 ----- | | | | | | | | | | | | | | |
| Sample B1 | | 1,16 | 0,14 | 12 | 13 | | | | | | | 10 | 10 | 100% |
| (60) Roche | | 1,09 | 0,096 | 8,9 | 8 | 0 | CVPG | 1,11 | 0,034 | 15% | 0,943 | 1,28 | 8 | |
| Other | | | | | 5 | 0 | | | | | | | 2 | |
| ----- 2x 24, 3x 29 ----- | | | | | | | | | | | | | | |
| Set 2 | | | | | | | | | | | | | | |
| (370) AFP | [µg/L] | | | | 14 | | | | | | | 11 | 10 | 91% |
| Samples and groups | | | | | | | | | | | | | | |
| Sample A2 | | 29,4 | 4,0 | 14 | 14 | | | | | | | 11 | 10 | 91% |
| (12) Beckman Coulter | | 25,1 | 1,6 | 6,4 | 5 | 0 | CVPG | 26,8 | 1,8 | 20% | 21,4 | 32,2 | 5 | |
| (60) Roche | | 31,2 | 0,98 | 3,1 | 5 | 0 | CVPG | 31,9 | 1,1 | 20% | 25,5 | 38,3 | 5 | |
| Other | | | | | 4 | 0 | | | | | | | 1 | |
| ----- 1x 1, 3x 179 ----- | | | | | | | | | | | | | | |
| Sample B2 | | 5,98 | 0,85 | 14 | 14 | | | | | | | 11 | 10 | 91% |
| (12) Beckman Coulter | | 5,40 | 1,0 | 19 | 5 | 0 | CVPG | 5,73 | 0,40 | 20% | 4,58 | 6,88 | 5 | |
| (60) Roche | | 6,33 | 0,29 | 4,6 | 5 | 0 | CVPG | 6,5 | 0,44 | 20% | 5,2 | 7,8 | 5 | |
| Other | | | | | 4 | 0 | | | | | | | 1 | |
| ----- 1x 1, 3x 179 ----- | | | | | | | | | | | | | | |
| (373) hCG | [kU/L] | | | | 14 | | | | | | | 10 | 10 | 100% |
| Samples and groups | | | | | | | | | | | | | | |
| Sample A2 | | 32,0 | 6,6 | 21 | 14 | | | | | | | 10 | 10 | 100% |
| (60) Roche | | 28,0 | 2,1 | 7,6 | 5 | 0 | CVPG | 27,4 | 0,99 | 18% | 22,4 | 32,4 | 5 | |
| Other | | | | | 9 | 0 | | | | | | | 5 | |
| ----- 1x 1, 4x 12, 1x 29, 1x 36, 2x 179 ----- | | | | | | | | | | | | | | |
| Sample B2 | | 101 | 28 | 28 | 14 | | | | | | | 10 | 10 | 100% |
| (60) Roche | | 89,9 | 3,9 | 4,3 | 5 | 0 | CVPG | 87,3 | 4,2 | 18% | 71,5 | 104 | 5 | |
| Other | | | | | 9 | 0 | | | | | | | 5 | |
| ----- 1x 1, 4x 12, 1x 29, 1x 36, 2x 179 ----- | | | | | | | | | | | | | | |
| (375) Estriol unconjug. | [nmol/L] | | | | 13 | | | | | | | 12 | 12 | 100% |
| Samples and groups | | | | | | | | | | | | | | |
| Sample A2 | | 2,37 | 1,0 | 43 | 13 | | | | | | | 12 | 12 | 100% |
| (12) Beckman Coulter | | 3,19 | 0,33 | 10 | 5 | 0 | CVPG | 3,22 | 0,13 | 33% | 2,15 | 4,29 | 5 | |
| (29) Siemens (Immulite) | | 1,67 | 0,22 | 13 | 7 | 0 | CVPG | 1,62 | 0,13 | 33% | 1,08 | 2,16 | 7 | |
| Other | | | | | 1 | 0 | | | | | | | 0 | |
| ----- 1x 999 ----- | | | | | | | | | | | | | | |
| Sample B2 | | 0,372 | 0,18 | 48 | 13 | | | | | | | 12 | 12 | 100% |
| (12) Beckman Coulter | | 0,480 | 0,044 | 9,1 | 5 | 0 | CVPG | 0,519 | 0,051 | 33% | 0,347 | 0,691 | 5 | |
| (29) Siemens (Immulite) | | 0,242 | 0,002 | 0,91 | 7 | 0 | CVPG | 0,24 | 0 | 33% | 0,16 | 0,32 | 7 | |
| Other | | | | | 1 | 0 | | | | | | | 0 | |
| ----- 1x 999 ----- | | | | | | | | | | | | | | |
| 1. trimester | | | | | | | | | | | | | | |
| (240) free beta-hCG (MoM) | [MoM] | | | | 8 | | | | | | | 8 | 8 | 100% |
| Samples and groups | | | | | | | | | | | | | | |
| Mother X1 | | 1,66 | 0,27 | 16 | 8 | | | | | | | 8 | 8 | 100% |
| (60) Roche | | 1,67 | 0,26 | 16 | 7 | 0 | CVPG | 1,59 | 0,078 | 33% | 1,06 | 2,12 | 7 | |
| Other | | | | | 1 | 0 | | | | | | | 1 | |
| ----- 1x 24 ----- | | | | | | | | | | | | | | |
| Mother Y1 | | 1,18 | 0,18 | 15 | 8 | | | | | | | 8 | 8 | 100% |
| (60) Roche | | 1,20 | 0,16 | 13 | 7 | 0 | CVPG | 1,18 | 0,051 | 33% | 0,79 | 1,57 | 7 | |
| Other | | | | | 1 | 0 | | | | | | | 1 | |
| ----- 1x 24 ----- | | | | | | | | | | | | | | |

Filter: Slovakia, minimal size of the groups n = 5

EQA round: VVV2/21 - Maternal Diagnostic Screening (Triple Test)

Deadline: 05.11.2021

| Test | [unit] | RoM | SD | CV [%] | N _{tot} | N _{out} | Comparability | | | | | | N _{eva} | N _{suc} | S _{rel} |
|--------------------------------------|--------|-------|-------|--------|------------------|------------------|---------------|-----------------------------------|------------------|-----|-------|-------|------------------|------------------|------------------|
| | | | | | | | AV | U _{AV} | D _{max} | LL | UL | | | | |
| (241) PAPP-A (MoM) | | | | | 12 | | | | | | | 10 | 10 | 100% | |
| Samples and groups | [MoM] | | | | | | | | | | | | | | |
| Mother X1 | | 0,120 | 0,015 | 12 | 12 | | | | | | | 10 | 10 | 100% | |
| (60) Roche | | 0,115 | 0,007 | 6,4 | 8 | 2 | CVPG | 0,11 | 0,046 | 33% | 0,073 | 0,147 | 8 | | |
| Other | | | | | 4 | 1 | | | | | | 2 | | | |
| | | | | | | | | 2x 24, 2x 29 | | | | | | | |
| Mother Y1 | | 0,613 | 0,10 | 16 | 12 | | | | | | | 10 | 10 | 100% | |
| (60) Roche | | 0,560 | 0,074 | 13 | 8 | 0 | CVPG | 0,575 | 0,028 | 33% | 0,385 | 0,765 | 8 | | |
| Other | | | | | 4 | 0 | | | | | | 2 | | | |
| | | | | | | | | 2x 24, 2x 29 | | | | | | | |
| 2. trimester | | | | | | | | | | | | | | | |
| (380) AFP (MoM) | | | | | 14 | | | | | | | 14 | 10 | 71% | |
| Samples and groups | [MoM] | | | | | | | | | | | | | | |
| Mother X2 | | 0,828 | 0,12 | 15 | 14 | | CVP | 0,804 | 0,033 | 23% | 0,619 | 0,989 | 14 | 11 | 79% |
| All results | | 0,828 | 0,12 | 15 | 14 | 0 | | | | | | | 14 | | |
| Mother Y2 | | 0,170 | 0,024 | 14 | 14 | | CVP | 0,169 | 0,066 | 23% | 0,13 | 0,208 | 14 | 13 | 93% |
| All results | | 0,170 | 0,024 | 14 | 14 | 0 | | | | | | | 14 | | |
| (382) hCG (MoM) | | | | | 14 | | | | | | | 10 | 9 | 90% | |
| Samples and groups | [MoM] | | | | | | | | | | | | | | |
| Mother X2 | | 0,989 | 0,14 | 14 | 14 | | | | | | | 10 | 9 | 90% | |
| (60) Roche | | 0,925 | 0,067 | 7,2 | 5 | 0 | CVPG | 0,991 | 0,086 | 33% | 0,663 | 1,32 | 5 | | |
| Other | | | | | 9 | 0 | | | | | | 5 | | | |
| | | | | | | | | 1x 1, 4x 12, 1x 29, 1x 36, 2x 179 | | | | | | | |
| Mother Y2 | | 3,00 | 0,53 | 18 | 14 | | | | | | | 10 | 10 | 100% | |
| (60) Roche | | 2,86 | 0,13 | 4,7 | 5 | 0 | CVPG | 3,07 | 0,26 | 33% | 2,05 | 4,09 | 5 | | |
| Other | | | | | 9 | 0 | | | | | | 5 | | | |
| | | | | | | | | 1x 1, 4x 12, 1x 29, 1x 36, 2x 179 | | | | | | | |
| (384) Estriol unconjug. (MoM) | | | | | 13 | | | | | | | 12 | 11 | 92% | |
| Samples and groups | [MoM] | | | | | | | | | | | | | | |
| Mother X2 | | 0,963 | 0,10 | 11 | 13 | | | | | | | 12 | 11 | 92% | |
| (12) Beckman Coulter | | 0,970 | 0,10 | 11 | 5 | 0 | CVPG | 1,03 | 0,064 | 33% | 0,69 | 1,37 | 5 | | |
| (29) Siemens (Immulin) | | 0,955 | 0,082 | 8,5 | 7 | 0 | CVPG | 0,949 | 0,11 | 33% | 0,635 | 1,27 | 7 | | |
| Other | | | | | 1 | 0 | | | | | | 0 | | | |
| | | | | | | | | 1x 999 | | | | | | | |
| Mother Y2 | | 0,149 | 0,014 | 9,4 | 13 | | | | | | | 12 | 11 | 92% | |
| (12) Beckman Coulter | | 0,145 | 0,007 | 5,1 | 5 | 0 | CVPG | 0,168 | 0,018 | 33% | 0,112 | 0,224 | 5 | | |
| (29) Siemens (Immulin) | | 0,145 | 0,007 | 5,1 | 7 | 0 | CVPG | 0,141 | 0,012 | 33% | 0,094 | 0,188 | 7 | | |
| Other | | | | | 1 | 0 | | | | | | 0 | | | |
| | | | | | | | | 1x 999 | | | | | | | |

st_kn_p

End of report

Printed: 15.11.2021